.svg)
.svg)
Transactions
By The Numbers
$100B+
Transaction Volume
200+
Completed Transactions
Biotech transactions
Roche
Advised Roche on their entrance into GLP-1 assets with Zealand Pharma
Sanofi
Advised Sanofi on the sale of anti-infective brands to FIDIA (April, 2024)
JBR Galderma
JBR Galderma IPO at CHF2.3bn (March, 2024)
DORC
Advised on sale of DORC to Zeiss for €1bn (Dec, 2023)
Werfen
Advised Werfen on acquisition of Immucor for $2bn (Nov, 2022)
Bestway Group
Exclusive Adviser to Bestway Group on acquisition of Lexon Group Plc (March, 2022)
Grunethal
Advised Grunethal on acquisition of Kyowa Kirin International European business (Nov, 2022)
NeuraxPharm
Exclusive Adviser to NeuraxPharm/Permira on acquisition of Sanofi CNS portfolio (July, 2022)
Doc Pharma
Advised ICG on the sale of Doc Generici to TPG (June, 2022)
EuroAPI
Lead adviser on spinoff and listing of EuroAPI from Sanofi (May, 2022)
Roche
Advised and financed Roche on $20.7 bn stake buy-back from Novartis (Nov, 2021)
Synlab
IPO Synlab (JBR; April 2021)
Contura
Exclusively advised Contura on sale of Bulkamid to Axonics (Feb 2021, $235m Feb 2021)
GC Pharma
Exclusively advised GC Pharma on sale of Canadian plasma fractionation facility to Grifols (July 2020, $460m)
Grifols
Exclusively advised GC Pharma on sale of Canadian plasma fractionation facility to Grifols (July 2020, $460m)
Premira
Exclusively advised Permira on acquisition of Quotient Sciences (July 2019)
Genus
Exclusively advised Genus on strategic partnership with Beijing Capital Co Ltd Agribusiness (May 2019; $20m upfront and $160m earnout)
Takeda
Advised and financed (Bridge then Bond) Takeda on $64bn acquisition of Shire (Jan 2019)
NMC Health
Advised NMC on acquisition of Al-Zahra (Dec 2016; $560m)
Acino
Exclusively advised Acino on acquisition of Litha, Endo’s South African business (Feb 2017)
Charterhouse Capital Partners
Advised Charterhouse on sale of Doc Generici to CVC (June 2016)
Ascendis Health
Advised Ascendis Health on acquisition of Remdica and Scitec (May 2016; €430m)
Endo Pharma
Exclusively advised Endo Pharma around divestment of their women’s health division (April 2016)
Bridgepoint
Advised Bridgepoint on sale of LGC to KKR (March 2016)
Valeant Pharma
Advised Valeant on acquisition of Salix (Feb 2015; $14.5bn)
Montagu Private Equity
Exclusively advised Montagu on stake sale of Euromedic to Ares lifesciences (2014)
Amgen
Advised Amgen on acquisition of Onyx (Aug, 2013; $10.5bn)
Bain Capital
Advised UK government on sale of Plasma Resources UK to Bain Capital (July 2013)
UK Government
Advised UK government on sale of Plasma Resources UK to Bain Capital (July 2013)
Ipsen
Advised Ipsen on acquisition of Syntaxin (July 2013; $211M)
Advisor Transactions
$12M
Advisor Transactions
$22m
Advisor Transactions
$2.9m
Advisor Transactions
$12M
Advisor Transactions
$5.9M
Advisor Transactions
$10.2M
Advisor Transactions
$6.2m
Advisor Transactions
$550m
Advisor Transactions
$5.2M
Advisor Transactions
$17M
Advisor Transactions
$150M
Advisor Transactions
$9.4m
Advisor Transactions
$1.2m
Advisor Transactions
$2.1b
Advisor Transactions
$360M
Advisor Transactions
Others
Advisor Private Family Fund Portfolio Highlights
A Leading Specialty Pharmacy
$350 - 400mm
An Specialized Defense Contractor
$100 - 125mm
A National Staffing Business
$100 - 125mm
Hope Capital Advisors was formed in 2025 - these transactions reflect work completed by advisors at their prior firms
.svg)
Copyright © 2025 Hope Capital Advisors. All Rights Reserved.